A qualitative exploration of the patient disease and treatment burden of end stage renal failure, Post-Renal transplantation and antibody mediated rejection (AMR)

The qualitative exploration of patient experience of symptoms and impacts carried out in our study underlines the heterogeneity of experience and the burden of disease and treatment experienced by patients at all stages of disease and treatment, from ESRD, to AMR of the kidney transplant. Eliciting these data directly from patients, analyzing and presenting these concepts in conceptual disease models is an essential step towards relevant and accurate measurement of patient experience in these populations.

Authors

Institutions

Publication Details

Journal
BMC Nephrology
Published
2025-09-29
DOI
https://doi.org/10.1186/s12882-025-04415-6
Citations
1
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
1.99

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A qualitative exploration of the patient disease and treatment burden of end stage renal failure, Post-Renal transplantation and antibody mediated rejection (AMR)

Paúl Cordero, JaneMaree Maher, Jane R. Wells, Amy Clark et al.
1 citations
BMC Nephrology
Renal Transplantation Outcomes and Treatments
1.99
article

A qualitative exploration of the patient disease and treatment burden of end stage renal failure, Post-Renal transplantation and antibody mediated rejection (AMR)

Paúl Cordero, JaneMaree Maher, Jane R. Wells, Amy Clark, Nicola Barnes, Nashmel Sargalo
article en
1 citations

Abstract

The qualitative exploration of patient experience of symptoms and impacts carried out in our study underlines the heterogeneity of experience and the burden of disease and treatment experienced by patients at all stages of disease and treatment, from ESRD, to AMR of the kidney transplant. Eliciting these data directly from patients, analyzing and presenting these concepts in conceptual disease models is an essential step towards relevant and accurate measurement of patient experience in these populations.

BMC NephrologyVol. 26(1)
Thermo Fisher Scientific (United Kingdom) (GB), Sanofi (United Kingdom) (GB), Thermo Fisher Scientific (Israel) (IL)
Sanofi
Openalex Percentile: Top 12%
Renal Transplantation Outcomes and Treatments
1.99
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.